Arimidex 1
$50.00
Iron Ascension Arimidex 1 (Anastrozole) is a selective, non-steroidal aromatase inhibitor (AI) engineered for precise systemic estrogen control and water retention mitigation. By binding competitively to the aromatase enzyme, it prevents the conversion of testosterone into estradiol, ensuring a dry physique while shielding against estrogen-related side effects.
Guaranteed safe checkout
Description
Description
Iron Ascension Arimidex 1
Specifications & Composition
| Specification | Details |
|---|---|
| Active Compound | Anastrozole |
| Concentration | 1 mg per tablet |
| Total Quantity | 60 tablets |
| Delivery System | Oral administration |
| Formulation Standard | Pharmaceutical grade (manufacturer claim; verification required) |
| Batch Testing | High-Performance Liquid Chromatography (HPLC) |
Key Performance Features
- Targeted Estrogen Suppression: Anastrozole is a non-steroidal aromatase inhibitor that reduces the conversion of androgens into estrogen. The degree of estradiol reduction varies between individuals and cannot be guaranteed at a fixed percentage.
- Estrogen and Fluid Balance: By reducing estrogen production, anastrozole may affect estrogen-related fluid changes. However, it does not guarantee prevention or elimination of subcutaneous fluid retention or produce a specific muscular appearance.
- Gynecomastia Considerations: Anastrozole may reduce estrogen production, but it is not a guaranteed preventive treatment for gynecomastia. Its effectiveness depends on the underlying cause and clinical context.
Important Health Considerations: Excessive estrogen suppression can cause joint pain, hot flashes, fatigue, reduced bone mineral density, increased fracture risk, and adverse cholesterol changes. Estrogen also plays important roles in male and female health. Medical supervision and appropriate laboratory monitoring are essential.
Quality Control & Lab Verification
The manufacturer reports that each batch undergoes quantitative testing before allocation.
| Quality Control Parameter | Reported Result |
|---|---|
| Compound | Anastrozole (oral tablets) |
| Assay Result | 99.7% active compound (reported) |
| Testing Method | HPLC (reported) |
| Verification Status | PASSED (reported) |
Publication note: The 99.7% assay result, HPLC report, pharmaceutical-grade designation, and tablet formulation should be verified against a genuine, batch-specific certificate of analysis. HPLC assay alone does not establish tablet uniformity, dissolution, contaminant absence, or product safety.
Specifications
- Short Stroke Gas Piston Gas System (Rifle Length)
- 18.6″ Barrel Length ( Mid-Weight style, non-fluted)
- 1:8 Twist Rate Rifling
Reviews
There are no reviews yet.